Topic: congressional hearing
Lawmakers are looking hard at bills targeting drug-price increases and competition—and as usual, pharma has responded by busting open the piggy bank.
The move comes as Lilly and the other two big diabetes drugmakers face increasing political pressure on rising insulin prices.
An influential senator said Teva is blocking her efforts to learn more about the company's opioid antidiversion programs.
Industry lobbying group PhRMA has cleared its decks of nearly two dozen members as it tries to distance itself from those companies most likely to catch heat over drug pricing practices.
Why didn't Medicaid officials go after Mylan for underpaying EpiPen rebates—and just how much did those years of underpayments cost the government?
The 21st Century Cures Act seeks to ease the path to FDA approval, but if Sen. Elizabeth Warren gets her way, the long-awaited bill could stall again.
Congress may be busy investigating Mylan and its EpiPen pricing, but that doesn’t mean its watchdog committees can’t turn a spotlight on pharmacy benefits managers, too. And a group of pharmacists is demanding that they do just that.
When Mylan CEO Heather Bresch testified before the House Committee on Oversight and Government Reform that each twin pack of EpiPens nets the company only $100 of its $600 list price, she got a skeptical response. Now the House is demanding details about the company's tax rate.
The Centers for Medicare and Medicaid Services says it repeatedly told Mylan that it had misclassified EpiPen for Medicaid rebate purposes, suggesting that the government-funded health program overpaid for the increasingly pricey product for years.
Mylan has been fighting for more than a year to block Teva’s generic EpiPen. But all along EpiPen itself has been classified as a generic drug for Medicaid patients--and now, U.S. senators are calling on the Justice Department to find out why.